EUCTR2006-006658-89-CZ进行中（未招募）1 期
A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 184
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Disease Related
- •Histologically or cytologically confirmed non-small cell lung cancer. Mixed tumors will be categorized by the predominant cell type unless small cell elements are present in which case the subject will be ineligible. Cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy.
- •Subjects must have advanced non-small cell lung cancer defined as stage IIIB
- •with malignant pleural effusion or stage IV or recurrent disease (recurrent
- •disease is defined as documented disease progression following complete
- •surgical resection for stage I or II disease). Subjects with non-measurable but
- •evaluable disease can be included in the study
- •Planning to receive up to 6 cycles of chemotherapy
- •Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- •Demographic
- •Men or women = 18 years of age
- •Before any study specific procedure is performed, the appropriate approved written
- •informed consent must be obtained
- •The following results must be obtained within 7 days before
- •enrollment/randomization unless indicated otherwise:
- •Hematological function as follows:
- •- Hemoglobin = 9 g/dL
- •- Absolute neutrophil count = 1.5 x 109/L
- •- Platelet count = 100 x 109/L (without a transfusion = 14 days prior to enrollment or randomization)
- •Renal function, as follows:
- •- Calculated creatinine clearance = 40 mL/minute
- •Hepatic function, as follows:
- •- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.5 x ULN
- •OR AST or ALT = 5.0 x ULN if clearly attributable to liver metastasis
- •- Total bilirubin = 1.5 x ULN
- •- Alkaline phosphatase = 2.0 x ULN OR alkaline phosphatase = 5 x ULN if liver or bone metastases are present
- •Partial thromboplastin (PTT) = 1.2 x ULN and international normalized ratio (INR)
- •= 1.5, unless subject is on anti-coagulation therapy. Subjects on therapeutic anticoagulation
- •are eligible if there is no bleeding and they are on a stable dose of
- •anticoagulation therapy (eg, on warfarin with an INR of 2 to 3) for at least 14 days
- •before enrollment/randomization
- •Amylase = 2 x ULN
- •Lipase = 2 x ULN
- •Plan to begin protocol specific therapy = 7 days prior to enrollment/randomization
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Disease Related
- •Untreated or symptomatic central nervous system metastases.
- •- Subjects with a history of CNS metastases that are both definitively
- •treated and stably controlled are eligible if all of the following apply:
- •1)definitive therapy has been administered (surgery and/or radiation
- •therapy); 2) there is no additional treatment planned for brain
- •metastases; 3) the subject is clinically stable; 4) the subject is off
- •corticosteroids or on a stable dose of corticosteroids for at least 14
- •days prior to enrollment/randomization•
- •Prior chemotherapy as follows:
- •- Any prior chemotherapy for advanced non-small cell lung cancer
- •- Any prior adjuvant or neo-adjuvant chemotherapy for non-small cell lung
- •cancer = 52 weeks prior to enrollment/randomization. Adjuvant or neoadjuvant
- •chemotherapy completed > 52 weeks prior to randomization is
- •- Any prior chemoradiation for non-small cell lung cancer.
- •Central (chest) radiation therapy = 28 days prior to randomization, radiation therapy for peripheral lesions = 14 days prior to enrollment/randomization
- •A history of other malignancies (except: curatively treated non-melanoma skin cancer, in-situ cancer of the cervix, or other in situ cancer with similarly favorable prognosis) unless treated with curative intent, with no treatment administered and without evidence of disease for = 3 years
- •Other abnormal medical conditions
- •Documented myocardial infarction or unstable/uncontrolled cardiac condition (eg,
- •unstable angina, congestive heart failure [New York Heart Association > Class II])
- •= 52 weeks prior to enrollment/randomization
- •History of arterial thrombosis, pulmonary embolus, deep vein thrombosis or hemorrhagic disorders = 28 days prior to enrollment/randomization
- •History of any medical or psychiatric condition or addictive disorder, or laboratory
- •abnormality that in the opinion of the investigator, may increase the risks associated with study participation or study treatments or may interfere with the conduct of the study or interpretation of study results
- •Major surgical procedure = 30 days prior to enrollment/randomization or not yet
- •recovered from prior major surgery
- •Minor surgical procedure = 7 days prior to enrollment/randomization or not yet recovered from prior minor surgery
- •Known positive test for human immunodeficiency virus, hepatitis C virus or acute or
- •chronic hepatitis B infection
- •Any co-morbid disease that would increase the risk of toxicity
- •Medications and other treatments
- •Currently treated or previously treated with biologic, small molecule, immunotherapy, or other agents to treat advanced non-small cell lung cancer
- •Recent infection requiring a course of systemic anti-infectives that was completed
- •= 7 days before enrollment/randomization (with the exception of uncomplicated urinary tract infection)
- •Yellow fever vaccination within 30 days of randomization
- •Subject is not able to tolerate intravenous drug infusions
- •Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or subject is receiving other investigational agent(s)
- •Subject of child-bearing potential is evidently pregnant or is breast feeding
- •Woman or man with partner of childbearing potential not consenting to use
- •adequate contraceptive precautions ie double barrier contraceptive methods (eg
- •diaphragm plus condom), or abstinence during the course of the study and for 3
- •months after the la
研究者
相似试验
进行中（未招募）
不适用
A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung CancerEUCTR2006-006658-89-BEAmgen Inc184
进行中（未招募）
1 期
A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung CancerEstudio fase 1b/2 de AMG 655 en combinación con Paclitaxel y Carboplatino como primera línea de tratamiento del cáncer de pulmón no microcítico avanzadoEUCTR2006-006658-89-ESAmgen Inc165
进行中（未招募）
1 期
A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung CancerEUCTR2006-006658-89-FRAmgen Inc165
进行中（未招募）
不适用
A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung CancerEUCTR2006-006658-89-HUAmgen Inc184
进行中（未招募）
不适用
A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung CancerStage IIIb/IV Non-Small Cell Lung CancerMedDRA version: 9.1Level: LLTClassification code 10029519Term: Non-small cell lung cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2006-006658-89-GBAmgen Inc169